Novo Nordisk Navigates Regulatory Milestones and Internal Scrutiny

The Danish pharmaceutical giant Novo Nordisk finds itself in a complex position, simultaneously celebrating significant regulatory approvals while addressing formal criticism from U.S. regulators and internal governance concerns. This confluence of events presents a nuanced picture for investors monitoring the company's trajectory.

Quarterly Report and Stock Performance Loom Large

Investor attention is now turning to the upcoming financial report scheduled for May 6, 2026, which will detail the company's first-quarter performance. This release is highly anticipated given the current pressure on the share price. Novo Nordisk's stock has declined approximately 32% since the start of the year and is currently trading at its 52-week low. The competitive landscape remains challenging, with Eli Lilly intensifying rivalry in the obesity treatment sector, more affordable alternative drugs entering the U.S. market, and the patent expiration for several key products on the horizon. Since assuming the CEO role in August 2025, Mike Doustdar has implemented efficiency measures. The company's 2026 outlook anticipates growth in international operations but expects U.S. revenues to decline.

A Wave of FDA Decisions: Approvals and a Warning

The U.S. Food and Drug Administration (FDA) has been at the center of recent developments for Novo Nordisk. On March 27, the agency approved Awiqli (insulin icodec), marking the world's first basal insulin designed for once-weekly administration. This authorization was based on the ONWARDS clinical trial program, involving approximately 2,680 patients, which demonstrated blood sugar control comparable to daily regimens. A U.S. market launch is planned for the second half of 2026.

Should investors sell immediately? Or is it worth buying Novo Nordisk?

Just over a week earlier, on March 19, the FDA granted approval for Wegovy HD, a higher-dose 7.2 mg version of the weight-loss medication. In clinical trials spanning 68 weeks, this formulation achieved an average weight reduction of 20.7%.

However, these successes are shadowed by an FDA warning letter issued on March 5. The regulator identified systemic deficiencies in the company's procedures for reporting adverse drug events. The inspection, conducted at the firm's New Jersey headquarters in early 2025, found that serious side effects—including fatalities and instances of suicidal ideation linked to GLP-1 drugs such as Ozempic and Wegovy—were not properly documented and reported. Novo Nordisk has stated it is working to resolve the issues.

Shareholder Meeting Reveals Governance Tensions

Internal governance has also come under the microscope. During the Annual General Meeting held on March 26, notable dissent emerged. Norges Bank Investment Management (NBIM), the manager of Norway’s sovereign wealth fund and a major shareholder, abstained from voting on the re-election of Board of Directors Chair Lars Rebien Sørensen. This move followed a recommendation from proxy advisor ISS, which raised concerns about board effectiveness and the concentration of power. Sørensen holds the dual roles of Chair for both the corporate board and the Novo Nordisk Foundation, which controls the majority of voting rights.

Despite these signals of internal scrutiny, shareholder proposals concerning dividend distributions and the adoption of financial reports were passed.

Ad

Novo Nordisk Stock: New Analysis - 30 March

Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated Novo Nordisk analysis...

DK0062498333 | NOVO | boerse | 69025004 |